Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple powder make central lines safer and more durable?

NCT ID NCT06451185

Disease control Sponsor: Liverpool Heart and Chest Hospital NHS Foundation Trust Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether adding a powder that helps stop bleeding under the usual clear dressing can keep central line sites cleaner and more secure. About 450 adults having heart surgery will take part. The main goal is to see if the powder helps the dressing last longer without needing an unplanned change.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 450 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2024

Expected to finish

Nov 2025

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Pre-Theatre Phase - Scheduled for insertion of an internal jugular CVC as part of their routine care Theatre Phase \- Successful insertion of an internal jugular CVC Exclusion Criteria: Pre-Theatre phase * Patients younger than 18 years of age * Patients scheduled cannulation with more than one sheath or catheter into an ipsilateral internal jugular vein * Patients with compromised skin integrity in the area to be covered with the CVC transparent dressing * Patients who are scheduled to be transferred to another hospital at any time during the trial observation period of seven days post randomisation Theatre phase * Randomisation system not available * Known allergy to study dressings * Trial dressings not available * Skin barrier product not available * Securement suture not practicable * The CVC insertion site cannot be covered with either a single conventional dressing or the haemostatic powder covered with a single transparent dressing * Central line has a subcutaneous tunnel * More than one ipsilateral central venous sheath or catheter in situ (or planned)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Central line are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Central line Central venous catheter Critical care Hemostatic Vascular access

Contacts and locations

Locations

  • Liverpool Heart and Chest Hospital NHS FoundationTrust

    Liverpool, Merseyside, L14 3PE, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.